Karlo Siirala

Partner, Member of the Finnish Bar, LL.M.

I advise private equity firms, financial investors, corporates, growth companies, founders and management teams on various types of corporate transactions, including mergers and acquisitions, buyouts, exits, and growth and minority investments. I have significant experience in executing complex cross-border transactions across a range of business sectors, with particular experience in the technology and life sciences sectors and regulated fields, such as banking, insurance and financial services.

I also advise fund managers and investors on a wide range of matters related to private investment funds, such as fund formation, co-investment and consortium arrangements, fund investments and secondary transactions.

I earned my law degree from the University of Helsinki. In addition, I hold an LLM degree from Columbia Law School, where I was recognised as a James Kent Scholar for outstanding academic achievement. I also have gained international experience through my secondment to a leading US law firm. I have been recognised as a Rising Star for Corporate/M&A/Private Equity in Finland in the IFRL1000 Rising Stars Expert Guide 2022.

I regularly lecture at law schools and client seminars on topics related to corporate law and mergers and acquisitions.

Latest references

We advised Bionto Oy, a company offering industrial bio-solutions, in a financing arrangement where Korpi Capital made a EUR 4 million seed equity investment in the company. The execution of the investment requires that certain conditions specified in the investment documentation are met. Bionto is a Finnish early-stage biotechnology company that develops and produces sustainable, profitable and safe biotechnological solutions to support the green transition, business objectives and societal goals of various industrial operators.
Case published 8.7.2024
We acted as the Finnish legal advisor for BHP in connection with an exploration alliance agreement entered into between BHP and Kingsrose Mining Limited under which BHP (through a wholly owned subsidiary) will provide funding for regional mineral exploration across areas of interest in Finland. As part of the arrangement announced on 22 May 2024, BHP and Kingsrose entered into two exploration alliance agreements, focusing on nickel and copper exploration in specified regions in Finland and Norway. In Finland, the alliance agreement covers Kingsrose’s four exploration reservations at the Central Finland project in the Kotalahti Nickel Belt, a 400 kilometre long greenstone belt which hosts the past producing Hitura, Kotalahti and Enonkoski nickel mines. The alliances follow from Kingsrose’s successful participation in the BHP Xplor program, a global accelerator program targeting innovative, early-stage mineral exploration companies to find the critical resources necessary to drive the energy transition. BHP is the largest mining company in the world by market capitalisation, producing essential commodities through its assets, including iron ore, metallurgical coal, copper and nickel, and moving into potash.
Case published 4.7.2024
We advised BYG4Lab, a portfolio company of the European growth buyout investor Keensight Capital, on its acquisition of Finbiosoft Oy, an innovative software company founded in 2011 with a mission to help laboratories reach higher quality and better efficiency. Founded in 1982, BYG4lab is a leading software company specialised in data management solutions for medical laboratories. The company is headquartered in France and employs nearly 110 people, of which approximately 40% are in R&D. Keensight Capital is a European growth buyout investor with deep expertise in technology and healthcare. Keensight Capital partners with the management teams of fast growing and profitable companies providing capital, strategic guidance and operational support.
Case published 14.3.2024
We advised Keensight Capital on the Finnish law aspects of the combination of Biovian and 3P Biopharmaceuticals, two leading biologics contract development and manufacturing organisations (CDMOs) backed by Keensight Capital, to establish 3PBIOVIAN, a new pan-European leader in its field. The combined group will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for drug substance and drug product, from preclinical to clinical development and commercial phases. With over 500 professionals, manufacturing sites in Pamplona-Noáin (Spain) and Turku (Finland) and its commercial office in Boston (USA), 3PBIOVIAN will become one of the main independent European bio-CDMOs. We advised Keensight Capital alongside Paul Hastings, Keensight Capital’s lead legal counsel in the transaction, and Strelia and Garrigues, who, respectively, advised Keensight Capital on Luxembourgian and Spanish legal aspects of the combination.
Case published 6.2.2024
We are advising Sanok Rubber Company S.A. on the acquisition of Teknikum Group Ltd. Teknikum Group is a European polymer technology company serving industrial customers in need of reliable rubber, plastic, silicone, polyurethane, and foam solutions. The group has approximately 600 employees and operates four production plants in Finland and one in Hungary, and a sales office in Germany. Sanok Rubber Company S.A. is the European leader in the field of rubber products, rubber-to-metal articles and combination of rubber with other materials for the automotive, construction, agriculture, pharmacy and household appliances. Sanok Rubber Company S.A. is listed on the Warsaw Stock Exchange and employs more than 3,000 people in Europe and North America. The completion of the transaction, conditional on regulatory approval, is expected to take place in the first half of 2024.
Case published 20.12.2023
Castrén & Snellman is the trusted partner for companies in the insurance sector both in Finland and internationally. We have assisted our clients in matters such as obtaining authorisation for activities transactions, such as insurance portfolio transfers and ownership control processes system acquisitions disputes outsourcing arrangements sales, marketing and insurance distribution matters. We have extensive experience in the insurance sector and decades of collaboration with supervisory authorities. We offer our clients our internationally recognised competence, clear thinking and solution-oriented experts.
Case published 5.12.2023
We acted as the legal and ESG advisor to Mérieux Equity Partners on the acquisition of a majority stake in Labquality through a leveraged buyout by its buyout fund, Mérieux Participations 4. Existing shareholders of Labquality, including Cor Group and the management, will reinvest a portion of their proceeds into the company in connection with the transaction. Headquartered in Helsinki, Finland, Labquality is a Nordic player specialized in EQA, CRO activities and regulatory affairs, with a strong local presence in Central and Eastern Europe. The company provides a comprehensive array of services for the healthcare, medical technology, and pharmaceutical industries. The company, employing over 120 professionals and supported by a network of more than 150 external experts and consultants across its offices in Finland, Germany, and Poland, serves a diverse clientele of over 8,000 customers, including major pharmaceutical companies in over 60 countries. Mérieux Equity Partners (MxEP) is an AMF-accredited management company dedicated to equity investments in the Healthcare and Nutrition sectors. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. The transaction will enable Labquality to pursue its buy & build strategy in Europe to accelerate its CRO activities while continuing strong and recurring growth in the EQA segment. Labquality will benefit from MxEP’s sector expertise and financial resources to achieve its ambition of becoming a leading European CRO and EQA platform, with fully integrated regulatory consulting capabilities to serve major customers across Europe.
Case published 4.12.2023
We advised Voisin Consulting Life Sciences (VCLS) on the acquisition of MedEngine, a leading medical science agency in the Nordics. MedEngine is a digitally minded, premium service provider for the pharmaceutical industry, built upon extensive academic expertise and years of experience in the industry. Founded in 2014, MedEngine has a strong presence across the Nordic countries with offices in Helsinki (Finland), Copenhagen (Denmark), and Stockholm (Sweden). Founded in 1997, VCLS provides end-to-end HealthTech solutions to support biotechnology, pharmaceutical and MedTech manufacturers throughout their product development. With offices in the US, France, UK, Switzerland, Denmark, Madagascar, India, and China, VCLS serves a broad range of developers and investors in HealthTech.
Case published 7.11.2023